Loading clinical trials...
Loading clinical trials...
This is a Single-masked Study to Compare Intravitreally Administered 0.5 mg Ranibizumab to 2.0 mg Ranibizumab in Subjects Who Manifest Persistent or Recurrent Macular Fluid Less Than 30 Days Following Treatment With Intravitreal Anti-VEGF Therapy.
Conditions
Interventions
Ranibizumab
Ranibizumab
Locations
1
United States
Vitreous Retina Macula Consultants of New York
New York, New York, United States
Start Date
May 1, 2010
Primary Completion Date
January 1, 2012
Completion Date
January 1, 2012
Last Updated
May 3, 2018
NCT07249216
NCT06787482
NCT04697095
NCT06683742
NCT03102138
NCT07424235
Lead Sponsor
Vitreous -Retina- Macula Consultants of New York
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions